Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DEGS1 | O15121 | 1/20 | 0.47 |
| ▸ | LPAR3 | Q9UBY5 | 2/20 | 0.46 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.46 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.45 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.45 |
| ▸ | DGKA | P23743 | 1/20 | 0.45 |
| ▸ | CETP | P11597 | 3/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.43 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16290473 | 1.00 | DEGS1 (0.47) | DEGS1LPAR3PLA2G4ASLC6A5PLA2G2C | |
| SCHEMBL16290467 | 0.98 | DEGS1 (0.47) | DEGS1LPAR3PLA2G4ASLC6A5PLA2G2C | |
| SCHEMBL10081428 | 0.98 | DEGS1 (0.47) | DEGS1LPAR3PLA2G4ASLC6A5PLA2G2C | |
| SCHEMBL14879498 | 0.95 | DNM1 (0.46) | DEGS1LPAR3PLA2G4ASLC6A5PLA2G2C | |
| SCHEMBL16099935 | 0.95 | DNM1 (0.46) | DEGS1LPAR3PLA2G4ASLC6A5PLA2G2C | |
| SCHEMBL28397254 | 0.94 | PLA2G2C (0.50) | SLC6A5PLA2G2CFAAHKMT2A | |
| SCHEMBL28397912 | 0.91 | PLA2G2C (0.48) | PLA2G2CFAAHKMT2A | |
| SCHEMBL10081362 | 0.88 | DNM1 (0.46) | DNM1DGKAPRKCEPRKCQPRKCD | |
| SCHEMBL15149519 | 0.87 | DNM1 (0.51) | LPAR3DNM1DGKAPRKCEPRKCQ | |
| SCHEMBL15149657 | 0.87 | DNM1 (0.51) | LPAR3DNM1DGKAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968149-B1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | DICERNA PHARMACEUTICALS INC (US) | 2024-05-08 | — | — | EP | disclosed |
| US-20220305130-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | NOVO NORDISK A/S (DK) | 2022-09-29 | — | — | US | disclosed |
| US-11351265-B2 | Process for formulating an anionic agent | DICERNA PHARMACEUTICALS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210292303-A1 | AMINE CATIONIC LIPIDS AND USES THEREOF | DICERNA PHARMACEUTICALS, INC. | 2021-09-23 | — | — | US | disclosed |
| US-11059807-B2 | Amine cationic lipids and uses thereof | DICERNA PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| EP-2768958-B1 | AMINE CATIONIC LIPIDS AND USES THEREOF | DICERNA PHARMACEUTICALS INC (US) | 2019-08-14 | — | — | EP | disclosed |
| US-20190151461-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | DICERNA PHARMACEUTICALS, INC. (US) | 2019-05-23 | — | — | US | disclosed |
| US-20190084965-A1 | AMINE CATIONIC LIPIDS AND USES THEREOF | NOVO NORDISK A/S (DK) | 2019-03-21 | — | — | US | disclosed |
| US-10144725-B2 | Amine cationic lipids and uses thereof | DICERNA PHARMACEUTICALS, INC. (US) | 2018-12-04 | — | — | US | disclosed |
| US-10137201-B2 | Process for formulating an anionic agent | DICERNA PHARMACEUTICALS, INC. (US) | 2018-11-27 | — | — | US | disclosed |
| US-20170137409-A1 | Amine Cationic Lipids and Uses Thereof | NOVO NORDISK A/S (DK) | 2017-05-18 | — | — | US | disclosed |
| US-9549983-B2 | Amine cationic lipids and uses thereof | DICERNA PHARMACEUTICALS, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| EP-2968149-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | Dicerna Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| US-20150374842-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | NOVO NORDISK A/S (DK) | 2015-12-31 | — | — | US | disclosed |
| US-20140371293-A1 | Amine Cationic Lipids and Uses Thereof | DICERNA PHARMACEUTICALS, INC. (US) | 2014-12-18 | — | — | US | disclosed |
| WO-2014153163-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | DICERNA PHARMACEUTICALS, INC. (US) | 2014-09-25 | — | — | WO | disclosed |
| EP-2768958-A1 | AMINE CATIONIC LIPIDS AND USES THEREOF | Dicerna Pharmaceuticals Inc. (US) | 2014-08-27 | — | — | EP | disclosed |
| WO-2013059496-A1 | AMINE CATIONIC LIPIDS AND USES THEREOF | DICERNA PHARMACEUTICALS, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190084965-A1 | AMINE CATIONIC LIPIDS AND USES THEREOF | SGMS2, SLC43A1, SGMS1 | DEGS1 610/4885LPAR3 17/4885PLA2G4A 234/4885 |
| US-11351265-B2 | Process for formulating an anionic agent | PHOSPHO1, POLRMT, LIPA | DEGS1 413/4885LPAR3 152/4885PLA2G4A 297/4885 |
| US-20190151461-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | PHOSPHO1, POLRMT, LIPA | DEGS1 413/4885LPAR3 152/4885PLA2G4A 297/4885 |
| US-10137201-B2 | Process for formulating an anionic agent | PHOSPHO1, POLRMT, LIPA | DEGS1 413/4885LPAR3 152/4885PLA2G4A 297/4885 |
| US-20220305130-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | PHOSPHO1, POLRMT, LIPA | DEGS1 413/4885LPAR3 152/4885PLA2G4A 297/4885 |
| US-10144725-B2 | Amine cationic lipids and uses thereof | SGMS2, SLC43A1, SGMS1 | DEGS1 610/4885LPAR3 17/4885PLA2G4A 234/4885 |
| US-11059807-B2 | Amine cationic lipids and uses thereof | SGMS2, SLC43A1, SGMS1 | DEGS1 610/4885LPAR3 17/4885PLA2G4A 234/4885 |
| US-20150374842-A1 | PROCESS FOR FORMULATING AN ANIONIC AGENT | PHOSPHO1, POLRMT, LIPA | DEGS1 413/4885LPAR3 152/4885PLA2G4A 297/4885 |
| US-20140371293-A1 | Amine Cationic Lipids and Uses Thereof | SGMS2, SLC43A1, SGMS1 | DEGS1 610/4885LPAR3 17/4885PLA2G4A 234/4885 |
| US-20170137409-A1 | Amine Cationic Lipids and Uses Thereof | SGMS2, SLC43A1, SGMS1 | DEGS1 610/4885LPAR3 17/4885PLA2G4A 234/4885 |
| US-20210292303-A1 | AMINE CATIONIC LIPIDS AND USES THEREOF | SGMS2, SLC43A1, SGMS1 | DEGS1 610/4885LPAR3 17/4885PLA2G4A 234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.